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Abstract. p16INK4a (p16) is a key molecule in bladder tumor 
(BT) development. We previously reported that a p16 antitumor 
peptide inhibited the growth of subcutaneous BT grafts in 
mice through restoration of p16 function using a Wr-T peptide 
transporter system. In the present study, the efficacy of mouse 
p16 peptide administration in a mouse lung metastasis model 
for BT and also the toxicity of peptides by cardiac peptide 
injection were evaluated. Mouse lung metastases were devel-
oped by tail vein injection of a p16‑deficient MBT‑2 cell line. 
Six-week-old C3H/He female mice were divided into three 
groups: A control group (n=12) receiving no treatment; a group 
treated once on the 3rd experimental day (n=12); and a group 
treated three times on the 3rd, 5th and 7th experimental days 
(n=10) with an injection of a mixture of 80 nmol mouse p16 
peptide and 50 nmol Wr-T into the tail vein. At the 14th experi-
mental day, the lung metastases were histologically evaluated. 
Lung metastases were observed in 100% (12/12), 41.7% (5/12) 
and 30% (3/10) of the aforementioned three groups, respec-
tively. The number and area of metastatic lung tumors were 
significantly different between control and treatment groups 
(control vs. triple treatment group for the number and area, 
P=0.0029 and P=0.0296, respectively). Immunohistochemistry 
demonstrated that phosphorylated retinoblastoma (Rb) 
protein was decreased in lung tumors of the treatment groups, 
compared with the control group. The toxicity of p16 peptide 
transduction was evaluated by using low-dose treatment (three 
dosages) and high-dose treatment (two dosages) on three male 
and three female C3H/He mice in early and late experimental 
phases. In low and high dose groups, no notable change was 
determined in body weight or blood analyses in early or late 
phases following mouse p16 peptide administration. In addi-
tion, no notable change was observed histologically in bone 
marrow of treatment groups. To conclude, systemic p16 peptide 
administration decreased lung tumor development in a mouse 
metastatic BT model without severe adverse events, as assessed 
by blood analyses and histological evaluation.
Introduction
Human urothelial carcinoma evolves via the accumulation of 
numerous genetic alterations, with the loss of p53 and p16INK4a 
(p16) function representing important stages in the develop-
ment of superficial lesions and their progression to malignant 
disease (1). p16 inhibits the activities of cyclin-dependent 
kinases, which maintain the retinoblastoma protein (pRb) in 
its active hypophosphorylated state (2).
A p16 gene transfection study demonstrated that growth 
arrest and suppression of tumorigenesis of bladder tumor (BT) 
cell lines may be induced by the p16 gene (3). It was reported 
that the p16 antitumor peptide notably inhibited the growth of 
highly aggressive leukemia/lymphoma types through restora-
tion of p16 function (4). In urological cancer types, growth of 
renal cell carcinoma cell line graft was also inhibited by trans-
duction of p16 peptide in mice (5). We previously reported the 
antitumor effect of a minimal inhibitory sequence peptide of 
p16 (p16-MIS) on allografts of solid tumor types, particularly 
urological cancer, derived from p16‑deficient BT cell lines 
using a Wr-T system (6). In the present study, the suppression 
of BT metastasis with a p16-Wr-T peptide transfer system 
using a metastasis model of BT in mice was demonstrated, 
continuing on from our previous study. In terms of animal 
models for BT metastasis, a mouse lung metastasis model 
using the MBT-2 cell line was selected due to lung metastases 
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occurring frequently, and at a similar rate to liver metastases 
(36 and 38%, respectively) (7). In addition, this animal model 
was established previously by Horinaga et al (8).
It has been reported that the current standard treatment for 
patients with systemic disease, including distant metastases of 
BT, is a combination of gemcitabine and cisplatin, including GC 
therapy (9). In addition, immune-checkpoint inhibitor, including 
pembrolizumab, anti-PD-1 antibody has been reported as a 
second treatment option for BT (10). Due to the fact that the 
aforementioned treatments may be associated with severe 
adverse events or specific immune‑associated reactions, new 
systemic treatments are not expected to present such adverse 
events. Therefore, the present study also evaluated the toxicity in 
mice associated with systemic p16 peptide transductions.
Materials and methods
Cells. The mouse BT cell line MBT-2 (Japanese Collection 
of Research Bioresources Cell Bank, National Institutes of 
Biomedical Innovation, Health and Nutrition, Osaka, Japan) 
was cultured in RPMI-1640 containing 10% inactivated fetal 
bovine serum (Immuno-Biological Laboratories, Co., Ltd., 
Fujioka, Japan) at 37˚C in a humidified atmosphere containing 
5% CO2. The MBT-2 cell line is a p16-deficient cell line 
with phosphorylation of the Rb protein (6). We previously 
confirmed the lack of expression of p16 in MBT‑2 and that 
restoration of p16 function by peptide transduction resulted in 
downregulation of phosphorylated Rb expression (6).
Mouse model for lung metastases. Six-week-old female 
C3H/He mice were obtained from Charles River Laboratories 
Japan, Inc. (Yokohama, Japan). The mice were kept under 
the following housing condition: 23.5±2.5˚C temperature; 
52.5±12.5% humidity; 200Lx illumination during daytime 
(5:00 to 19:00), and free access to food and water. A total of 
100 µm suspension containing 1x105 MBT-2 cells in PBS was 
injected into the tail vein of each mouse, and lung metastases 
had developed when the mice were sacrificed by cervical 
dislocation on the 14th experimental day, based on the previous 
study by Horinaga et al (8). Horinaga et al (8) observed lung 
metastases between the 9th and 12th day after tail vein injec-
tion of MBT-2 cells and survival of mice decreased at the 15th 
day after injection. In addition, in our pilot study, a number of 
mice succumbed to severe lung metastases at the 21st day after 
injection (data not shown). In total, 34 mice were classified 
into three groups: A control group (n=12); a single treatment 
group (n=12); and a triple treatment group (n=10). A decreased 
number of mice were used in the triple treatment group due to 
failure (i.e., phlebitis and hematoma) of the tail vein injection 
during the process of experiments. The initial body weight 
of mice in the aforementioned three groups were 18.5±1.19, 
19.2±0.970, and 18.7±0.633 g, respectively. At the end of the 
experiment the body weight of mice were 19.7±1.13, 20.1±0.999, 
and 20.0±1.22 g, respectively. Animal experiments performed 
in the present study were approved by the Laboratory Animal 
Resource Center of the University of Tsukuba (Tsukuba, Japan). 
All mouse procedures, euthanasia and surgery, including injec-
tions of BT cells and peptides, were conducted painlessly or 
under anesthesia using a combination of hydrochloric acid 
medetonidine 0.3 mg/kg + midazolam 4 mg/kg + butorphanol 
tartrate 5 mg/kg within the strict guidelines of the Laboratory 
Animal Resource Center of the University of Tsukuba.
Peptide synthesis. All peptides including Wr-T and the 
r9-p16 MIS for mouse were synthesized at BioGate Co. Ltd. 
(Yamagata, Gifu, Japan) using standard fluorenylmethyloxy-
carbonyl chemistry as previously described (6). Briefly, the 
10 amino acid residue sequence, FLDTLVVLHG, was identi-
fied as the MIS of p16 (11), and the amino acid sequence of the 
Wr‑T transporter peptide was identified as KET WWE TWW 
TEW WTE WSQ GPG rrr rrr rrr (r, D-enantiomer arginine), 
as previously described (5,6). Peptides were purified at 95% 
by reverse-phase high-performance or high-pressure liquid 
chromatography using Shimadzu System Control HPLC 
10AVP (Shimadzu Corporation, Kyoto, Japan), according to 
the manufacturer's protocols, and a Shimadzu C18 Analytical 
column (Shimadzu Corporation). Identification of all peptides 
was confirmed by mass spectrometry (AXIMA CFR Kratos; 
Shimadzu Corporation). All peptides precipitated from 
trifluoroacetic acid solutions are trifluoroacetic acid salts. 
The hydrochloride form of peptides was prepared following 
high‑performance liquid chromatography purification.
Peptide transduction. In vivo peptide delivery to the lung 
metastatic tumor model of mice was performed by injecting 
the Wr-T/r9-p16 MIS peptide mix (Wr-T, 50 nmol; and r9-p16 
MIS, 80 nmol) into the tail vein. Following the MBT-2 cell 
injection, the peptide mix was delivered by tail vein injection 
on the 3rd day or the 3rd, 5th, and 7th days for the single and 
triple treatment group, respectively. The control group received 
no tail vein injection.
Evaluation of lung metastases following peptide transduction. 
Lungs were fixed in 10% neutral buffered formalin (Fujifilm 
Wako Pure Chemical Corp., Tokyo, Japan) overnight at room 
temperature and subsequently embedded into paraffin. Serial 
sections (4 µm) were used for hematoxylin and eosin (H&E) 
and immunohistochemical staining. The sections were stained 
with hematoxylin and eosin for 1.5 and 4 min, respectively, 
at room temperature. Lung metastases following the peptide 
transfer were evaluated histologically by H&E staining under 
a light microscope (magnification x40‑400; OLYMPUS BX41; 
Olympus Corp., Tokyo, Japan). To evaluate lung metastases, 
the number and size of metastatic nodules in each group was 
quantified using ImageJ 1.48v (National Institutes of Health, 
Bethesda, MD, USA). The number of metastases was counted 
on random H&E-stained sections of lungs from each mouse. 
Additionally, the size of the tumor was represented by the 
area of the tumor, calculated by tracing its contour line, on 
the H&E-stained sections, using ImageJ 1.48 software. For 
the number and area of the tumor samples, the differences 
between groups were analyzed.
Immunohistochemical staining of p16‑associated molecules 
and terminal deoxynucleotidyl transferase‑mediated 
dUTP‑biotin nick‑end labeling (TUNEL) staining transduction. 
Lungs were fixed in 10% neutral buffered formalin over-
night at room temperature and subsequently embedded into 
paraffin. According to previous studies (6,12), 4-µm serial 
paraffin sections were stained using a rabbit polyclonal 
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anti-phospho-Ser780 pRB antibody (dilution, 1:100; cat. 
no. 9307S; Cell Signaling Technology, Inc., Danvers, MA, USA) 
overnight at 4˚C, followed by the Universal Immuno‑enzyme 
Polymer method using the N‑Histofine Simple Stain Mouse 
MAX PO reagent (cat. no. 714342; Nichirei Biosciences, Inc., 
Tokyo, Japan), according to the manufacturer's protocol. The 
sections were developed with 3,3'-diaminobenzidine tetrahy-
drochloride containing 0.03% hydrogen peroxide for 5 min at 
room temperature and counterstained with hematoxylin for 
90 sec at room temperature. Apoptotic cells were detected in 
tumors harvested from mice 48 h after the peptide adminis-
tration. Apoptosis in tumor sections was determined by the 
TUNEL assay method with the use of ApopTag Peroxidase In 
Situ Apoptosis Detection kit (cat. no. S7100; Nippon Chemi-Con 
Co., Tokyo, Japan), according to the manufacturer's protocol. 
Histological findings were observed in five fields under a light 
microscope (magnification, x400; OLYMPUS BX41; Olympus 
Corp., Tokyo, Japan).
Evaluation of toxicity of systemic p16 MIS peptide transfer. To 
evaluate the toxicity of systemic p16 MIS peptide transduction, a 
single low or high dose of the p16 MIS peptide was injected into 
the hearts of mice as follows: A single low dose peptide transfer 
was defined as 5 nmol Wr‑T and 20 nmol p16 MIS; and a single 
high dose was defined as 25 nmol Wr‑T and 100 nmol p16 MIS. 
In contrast, late phase multiple high dose peptide transduction 
was evaluated at 12 weeks after the initial peptide administra-
tion, followed by four weekly peptide transfers of 25 nmol Wr-T 
and 100 nmol p16 MIS, respectively. There was no group with 
multiple low dose peptide transduction in late phase. Each group 
including the control group contained three male and three female 
mice, and toxicities were evaluated by body weight and blood 
analyses, which included a whole blood count and biochemistry, 
and by histological examination, including aforementioned H&E 
staining of bone marrow, thymus, lung, bronchus, pericardium, 
stomach, intestine, liver, spleen, kidney, testis, ovary and brain of 
mice. The mice used for toxicity evaluation were obtained from 
Japan SLC, Inc. (Hamamatsu, Japan) and were kept under the 
same housing condition previously described.
Statistical analyses. Each value in blood analyses and body 
weight was presented as the mean ± standard deviation. 
Statistical analysis was performed with JMP® 9.0.0 supported 
by SAS (SAS Institute Inc., Cary, NC, USA). One way analysis 
of variance (ANOVA) and the post-hoc Steel-Dwass test 
(non-parametric test) were used to compare the number and 
area of lung metastases, the blood analyses and animal body 
weight between groups. P<0.05 was considered to indicate a 
statistically significant difference.
Results
Inhibition of lung metastasis of BT cells following tail vein 
injection of p16 MIS peptide in a mouse lung metastasis model. 
Due to the practical potential of the Wr-T and p16 MIS peptide 
delivery system, the efficacy and toxicity of this system for the 
treatment of lung metastasis of MBT-2 mouse BT cells in C3H 
mice was investigated. At the 14th day after BT cell injection, 
lung metastases were observed in 100% (12/12), 41.7% (5/12) 
and 30% (3/10) of control, single and triple doses of p16 groups, 
respectively. Lung tumors were notably decreased in number 
and size in the p16 MIS peptide transfer groups, compared 
with the control group (Fig. 1).
A statistically significant decrease in tumor number and 
size was observed in the p16 peptide groups, compared with 
the control group (control vs. single or triple doses of p16 MIS 
peptide for the number, P=0.0087 and 0.0029, and in area, 
P=0.0183 and 0.0296, of tumors, respectively; Fig. 2).
Change in expression of p16‑associated molecules and apop‑
tosis after p16 peptide treatment. Fig. 3A, B and C demonstrate 
H&E staining, immunohistochemistry using an antibody 
against phosphorylated Rb, and TUNEL staining in control 
group, respectively. In H&E staining, no microscopic change 
in lung metastasis was observed between control and triple p16 
MIS peptide treatment group (Fig. 3D). The expression of Rb 
phosphorylation was notably decreased in the triple p16 MIS 
peptide treatment group (Fig. 3E), compared with the control 
group (Fig. 3B). The TUNEL staining demonstrated that apop-
tosis was increased in the triple p16 MIS peptide treatment 
group (Fig. 3F) compared with the control group (Fig. 3B).
Toxicity of systemic transduction of the p16 MIS peptide 
assessed by body weight, blood analyses and histological 
data. Changes in blood count and biochemistry following a 
single treatment in the early phase of the 2nd experimental 
Figure 1. Histological results of the lungs of mice in (A) control group with no p16 MIS peptide treatment (B) single p16 MIS peptide treatment group (p16x1) 
and (C) triple p16 MIS peptide treatment group (p16x3). Histological data of the lung at the 14th experimental day after MBT-2 administration via the mouse 
tail vein demonstrates that lung metastases are inhibited in number and size in the groups administered with the p16MIS peptide (B and C), compared with the 
control group (A). In the group with triple p16MIS peptide injection (C), metastases was rarely observed in the lung (magnification, x40). Note that the arrows 
indicate metastatic nodules.
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week are demonstrated in Table I and indicated no significant 
statistical difference between control and p16 MIS peptide 
treatment groups in both males and females. Changes in mouse 
body weights during administration of multiple p16 MIS doses 
are displayed in Table II. No significant statistical difference 
was observed in body weight between groups. Additionally, 
Table III indicates that no statistical difference in blood tests 
between the control and multiple p16 peptide treatment groups 
was observed in the late phase of the 12th experimental week. 
The white blood cell count was reduced in the group with 
multiple treatments, but there was no statistical difference.
There was no histological change observed in the thymus, 
lung, bronchus, pericardium, stomach, intestine, liver, spleen, 
kidney, testis, ovary, brain or bone marrow. No severe 
Figure 2. Number and size of lung metastases of MBT-2 cells control group and groups following p16 MIS peptide treatment. (A) Number of lung metastases 
in control group and groups with single and triple p16 MIS peptide treatment. For the number of lung metastases, the significance for control vs. p16x1 or 
p16x3 was P=0.0087 and P=0.0029, respectively (B) Size of lung metastases in control group and groups with single and triple p16 MIS peptide treatment. The 
significance for the area of metastases was P=0.0183 and P=0.0296 for control vs. p16x1 or p16x3, respectively. Quantitative evaluation demonstrated that the 
number (A) and size (B) of metastases in histological sections were statistically different between the p16 MIS peptide transduction and control groups. p16x1, 
single treatment of p16 MIS peptide; p16x3, triple treatments of p16 MIS peptide.
Figure 3. Histological findings of H&E staining, phosphorylated Rb immunohistochemistry and TUNEL staining in lung metastasis of control and p16 MIS 
peptide treatment group. (A) H&E staining of control group. (B) Phosphorylated Rb immunostaining of control group. (C) TUNEL staining of control group. 
(D) H&E staining of p16 MIS peptide treatment group. (E) Phosphorylated Rb immunostaining of p16 MIS peptide treatment group. (F) TUNEL staining of 
p16 MIS peptide treatment group. Rb phosphorylation decreased in p16 MIS peptide treatment group (E) compared with control group (B). In TUNEL staining, 
apoptosis was detected in p16 MIS peptide treatment group (F) compared with control group (C). Magnification, x400. H&E, hematoxylin and eosin.
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myelosuppression was histologically observed in the bone 
marrow subsequent to systemic p16 MIS peptide transduc-
tion (Fig. 4).
Discussion
In the present study, systemic transduction of the p16 MIS 
antitumor peptide successfully inhibited lung metastasis induced 
by venous injection in a dose-dependent manner. The decrease 
in the number and size of metastatic nodules, as demonstrated 
by histological data, indicated that the anti-metastatic effect may 
be based on inhibition of implantation and growth of tumor cells 
by cell cycle arrest (6) and that it induced apoptosis signaling. 
Immunohistochemistry also indicated that a candidate indicator 
to predict the anti-metastatic activity of the p16 MIS peptide 
could be the elevated expression of phosphorylated Rb in 
BT cells, due to p16 expression not always being absent or 
decreased but also it is overexpressed in a number of BT types, 
as previously described (6,13,14).
In previous studies regarding in vivo transduction of the 
antitumor peptide, adverse effects were not investigated (6,15); 
therefore, in the present study, whether or not systemic 
transduction of the p16 MIS peptide could cause toxicities of 
normal organs was analyzed using blood tests and histological 
data. Furthermore, systemic p16 peptide transduction did 
not inhibit the function of vital organs and bone marrow at 
the early and late phases following peptide administration. 
Although a number of statistical differences were observed in 
serum transaminase, no association with hepatic dysfunction 
was apparent. In H&E-stained sections, no notable histological 
difference was observed between control and p16 MIS peptide 
transfer groups at any experimental stage. This may indicate 
that overexpression of p16 would not suppress non-tumorous 
cells in mice, regardless of the activation state of proliferation.
Although the p16 MIS peptide used in the present study 
would be transferred into various cells in a non-selective 
manner, metastatic tumor in the lung could be a good candidate 
for non‑specific transduction, for example the peptide from the 
present study following injection into the systemic circulation. 
Higa et al (16) developed a novel cancer-homing peptide, which 
has a high affinity to the cell‑penetrating peptide with p16 MIS 
peptide, to glioblastoma cells. They screened cell-penetrating 
peptides as a novel biomedical delivery system and fused it 
with a functional p16 MIS peptide to improve therapeutic 
efficacy and decrease side effects on normal tissues (17,18). 
This system may become an ideal therapeutic system using 
functional peptides to improve antitumor activity against lung 
metastases of the present model in the future.
It may indicate that lung metastases can be controlled 
by the inactivation of a p16-associated cell cycle activator, 
Table I. Change in blood analyses of single treatment.
A, Male
Group Alb (g/dl) ALT (U/l) AST (U/l) Creat (mg/dl) WBC (/µl) RBC (104/µl) Hb (g/dl) Plt (104/µl)
Controla 3.3 86 30 0.01 5,430 748 12.4 37.8
 (0.06) (23) (11.5) (0.02) (1,036) (34.8) (0.62) (7.0)
20 nmola 3.5 74 19 0.02 5,207 741 11.7 35.5
 (0.27) (17) (3.1) (0.02) (1,952) (127.7) (2.1) (16.5)
100 nmola 3.2 60 16 0.05 6,160 805 13.0 60.2
 (0.15) (8.7) (1.7) (0.01) (1,384) (30.6) (0.1) (15.0)
P-value 0.779 0.189 0.179 0.176 0.900 0.390 0.784 0.188
B, Female
Group Alb (g/dl) ALT (U/l) AST (U/l) Creat (mg/dl) WBC (/µl) RBC (104/µl) Hb (g/dl) Plt (104/µl)
Controla 3.5 81 22 0.07 6,360 783 13.0 54.0
 (0.28) (5.0) (5.6) (0.01) (2,786) (7.07) (0.0) (1.78)
20 nmola 3.7 91 19 0.1 3,430 873 14.4 52.2
 (0.36) (3.0) (2.3) (0.03) (1,488) (55.9) (1.3) (15.0)
100 nmola 3.6 82 26 0.08 5,763 816 13.9 50.3
 (0.17) (1.0) (5.6) (0.02) (1,762) (27.7) (0.06) (8.5)
P-value 0.944 0.999 0.955 0.824 0.999 0.309 0.281 0.955
an=3. Alb, albumin; ALT, alanine aminotransferase; AST, aspartate amino transferase; Creat, creatinine; WBC, white blood cell; RBC, red 
blood cell; Hb, hemoglobin; plt, platelet; P16, p16INK4a; MIS, minimal inhibitory sequence; 20 nmol, the group of a single low dose peptide 
transfer with 5 nmol Wr-T and 20 nmol p16 MIS; 100 nmol, the group of a single high dose peptide transfer with 25 nmol Wr-T and 100 nmol 
p16 MIS. Each value is presented as the mean ± standard deviation (in brackets). The difference between groups was statistically analyzed by 
one way ANOVA and the post-hoc Steel-Dwass test (non parametric test). P-values between the control and 100 nmol groups are indicated.
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including phosphorylated Rb, as demonstrated in the immu-
nohistochemistry of the present study. Considering that p53 
may be a key molecule in BT, restoration of p14 or p21, as an 
activator of impaired p53 function, could inhibit lung metas-
tases. Kondo et al (15) previously reported that simultaneous 
induction of two tumor suppressor peptides (p14 and p16 or 
p16 and p21) suppressed the growth of a glioblastoma cell line 
that contained a missense mutation in p53.
Another possible strategy could be combination with a 
novel molecular target detected with whole genome mRNA 
expression profiling (19). For instance, although one of the 
key genes, fibroblast growth factor receptor 3 (FGFR3), has 
detected muscle invasive bladder cancer by the MD Anderson 
Cancer Center molecular subtyping (19,20), it was recently 
reported that FGFR3 mutations have a limited role in urothe-
lial carcinogenesis and must collaborate with other genetic 
events, including inactivation of pRb/p53 (21). Therefore, a 
combination therapy of functional peptide transduction with 
an FGFR3 inhibitor, such as BGJ398 (22), may demonstrate 
an enhanced inhibition of advanced bladder cancer cells in the 
future.
A limitation of the present study was the lack of information 
regarding in vivo kinetics in mice following administration of 
the p16 MIS peptide. If the accumulation of p16 MIS peptide 
in lung and metastatic tumor is detectable using whole-body 
fluorescent imaging, for example the IVIS Imaging System, 
it could assist with analyzing the biological modification of 
p16-associated molecules following peptide transduction in 
mice. Additionally, immunogenicity of the p16 MIS peptide 
should be analyzed to predict the production of antibodies 
against this peptide, which may be a limitation of future 
clinical application.
Table II. Change in body weight.
A, Male
Group Day 0 (g) Day 7 (g) Day 14 (g) Day 21 (g)
Controla 20.5 38.5 42.6 44.7
 (0.305) (3.10) (3.30) (5.00)
100 nmola 21.2 38.2 44.9 47.5
 (0.173) (0.451) (0.721) (2.78)
P-value 0.077 0.999 0.663 0.663
B, Female
Group Day 0 (g) Day 7 (g) Day 14 (g) Day 21 (g)
Controla 20.5 33.3 35.6 38.0
 (0.737) (2.41) (1.77) (1.45)
100 nmola 20.8 31.3 34.1 36.9
 (0.814) (1.34) (4.16) (4.17)
P-value 0.507 0.383 0.663 0.663
an=3. P16, p16INK4a; MIS, minimal inhibitory sequence; 100 nmol, the group of multiple high dose peptide transfer with 25 nmol Wr-T and 
100 nmol p16 MIS. Each value is presented as the mean ± standard deviation (in brackets). The difference between control and 100 nmol 
groups at each experimental day was statistically analyzed by one way ANOVA and the post-hoc Steel-Dwass test (non parametric test).
Figure 4. Histological findings of bone marrow of mice in (A) control and (B) p16 MIS peptide treatment group. No notable change was observed between 
control (A) and p16 MIS peptide treatment groups (B). Original magnification, x400.
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To conclude, systemic administration of the p16 MIS peptide 
through the tail vein significantly inhibited the number and size 
of lung metastases of BT in mice models. The toxicity of the 
p16 MIS peptide had no notable effect on the mice, according 
to blood and histological analyses, following short and long 
exposures to even a high dose of the peptide.
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